Prophylaxis of chronic adenoiditis in the children

Карпова, Е. П.; Karpycheva, I E; Тулупов, Д. А.

doi:10.17116/otorino201580643-45

Cited by 9 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that treatment with oropharyngeal probiotic reduced the exacerbation frequency of chronic adenoiditis and the requirement for medication ( 43 ). A similar beneficial effect of oropharyngeal complementary treatment was observed in our study, during intervention period; when acute respiratory symptoms onset, children complementary treated with oropharyngeal ENT-K12 in combination with medication (3 courses in total; 1 took antibiotics for 1 day and 2 took antiviral drugs for 1 and 2 days, respectively) or without medication further shortened the duration of respiratory symptoms onset compared to those treated with only medication in control group (14 courses in total; prescribed with antibiotics, antiviral drugs or antipyretics for various period of time from 1 to 10 days).…”

Section: Discussionmentioning

confidence: 99%

Oropharyngeal Probiotic ENT-K12 as an Effective Dietary Intervention for Children With Recurrent Respiratory Tract Infections During Cold Season

et al. 2022

View full text Add to dashboard Cite

Recurrent respiratory tract infections (RRTi) cause a high burden of disease and lead to negative impact on quality of life, frequent school/work absenteeism, and doctor visits, which remain a great challenge to pediatricians because RRTi can increase the risk of various complications including antibiotic overuse and resistance, which is one of the biggest threats to global health, and there is no confirmed effective treatment. In this study, we aimed to assess the clinical efficacy and safety of oropharyngeal probiotic ENT-K12 as a dietary intervention or a complementary treatment along with standard medical treatment during acute respiratory infections among children with RRTi during cold season. The results of this study show that when comparing to practicing of standard medical treatment only, the complementary intake of oropharyngeal probiotic ENT-K12 can effectively reduce episodes of both acute and RRTi in school children, shorten the course of respiratory symptoms onset, reduce the use of antibiotics and antiviral drugs, and reduce the absence days from both children's school and parents' work. Using oropharyngeal probiotics as a complementary dietary intervention to stabilize oropharyngeal microflora, specifically inhibiting respiratory pathogens and enhancing host immunity, could possibly be a promising approach to reduce RRTi burden and combating antibiotic resistance in long term, more clinical studies will be needed to further confirm the clinical practicing guide to ensure its clinical benefit.MethodsA total of 100 susceptible children with RRTi aged 3–10 years, living in Wuhan, China, were selected. They were randomized to the probiotic group and control group at the beginning of the trial during the cold season. Fifty children in the probiotic group took oropharyngeal probiotic ENT-K12 for 30 days, along with standard medical treatment when there was an onset of respiratory symptoms and medical treatment was needed, and fifty children in the control group did not take oropharyngeal probiotics but only had standard medical treatment when there was an onset of respiratory symptoms and medical treatment was needed. Patients were followed up for 30 days during the cold season. The primary objective of this study is to assess the complementary dietary interventional efficacy of oropharyngeal probiotic ENT-K12 on episodes of respiratory tract infections during the cold season, and the secondary objective is to assess the interventional efficacy of oropharyngeal probiotic on days of respiratory symptoms onset, using antiviral drugs, antibiotics, and antipyretics, days of children absent from school, and days of parents absent from work, as well as to confirm tolerability and safety judged by adverse event reporting.ResultsThere were 47 children, 22 male and 25 female children, with an average age of 5.71 years (SD = 1.99) in the probiotic group finishing the study, and 50 children, 32 male and 18 female children, in the control group with an average age of 6.12 years (SD = 1.98) finishing the study. During the 30-day period of oropharyngeal probiotic intake, children in the probiotic group totally had 7 episodes of upper respiratory tract infections, while children in the control group totally had 17 episodes of upper respiratory tract infections, indicating that the incidence of upper respiratory tract infection in the probiotic group (14.89%) was significantly lower than that in the control group (34.00%) during the intervention period. The days of using antibiotics and antiviral drugs in the probiotic group were significantly lower than that in the control group, and the course of respiratory symptoms onset was shorter and more moderate in the probiotic group than that in the control group; in addition, compared with the control group, both the days of children absent from school and parents' absence from work in the probiotic group were significantly lower. Children treated with oropharyngeal probiotic ENT-K12 had excellent tolerability with no side effects reported, hence confirmed safety of applying oropharyngeal probiotic ENT-K12 as a prophylactic use or an effective dietary intervention along with standard medication during respiratory infections onset.ConclusionIntake of oropharyngeal probiotic ENT-K12 as a dietary intervention can effectively reduce episodes of upper respiratory tract infections in school children with RRTi during high peak season, reduce the days of using antibiotics and antiviral drugs, and reduce children's sick leave days, parents' absence days from work, and shorten the course of respiratory infections; the safety of oropharyngeal probiotic ENT-K12 has been confirmed with no side effects reported, excellent tolerability, and easy acceptance. Notably, this study opens up a new research idea in the field of microbe promoting human health by supplying direct proof to support its efficiency and safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Oropharyngeal Probiotic ENT-K12 as an Effective Dietary Intervention for Children With Recurrent Respiratory Tract Infections During Cold Season

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For one article, statistical analysis was not reported [34]. We therefore carried out statistical analysis of their reported data using GraphPad QuickCalcs (https://www.graphpad.com/quickcalcs).…”

Section: Discussionmentioning

confidence: 99%

“…One study investigated the use of SsK12 as a prophylactic treatment to protect children with chronic adenoiditis against episodes of exacerbation [34]. This was a noneplacebo-controlled RCT involving 250 children aged 6 to 7 years.…”

Section: Exacerbation Of Chronic Adenoiditismentioning

confidence: 99%

“…Only one article reported adverse effects [34]. Three participants in the treatment group (3%) developed an urticarial rash and were therefore moved to the control group.…”

Section: Adverse Effectsmentioning

confidence: 99%

“…Di Pierro et al [21] reported that compliance with treatment was 'very good' and that no children withdrew from the study; however, actual adherence values were not reported. Karpova et al [34] did not report on compliance and excluded any children with intolerance to the probiotic from the trial; however, the number of children excluded for this reason was not reported. The one study that reported on the use of SsK12 for acute pharyngotonsillitis excluded three patients (10%) from the probiotic group and four (13%) from the placebo group for lack of compliance with treatment [35].…”

Section: Adverse Effectsmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of the probiotic Streptococcus salivarius K12 for the treatment and/or prevention of sore throat: a systematic review

Wilcox

Stuart

Leaver

et al. 2019

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Background: Sore throat resulting from pharyngotonsillitis is one of the commonest reasons for primary care consultation and inappropriate antibiotic prescription and finding effective alternative treatments is important. Objectives: To review the evidence for using the probiotic Streptococcus salivarius K12 (SsK12) for the prevention or treatment of pharyngotonsillitis. Data Sources: PubMed, Embase, CINAHL and Cochrane Library. Study eligibility criteria: Randomized controlled trials (RCTs). Participants: Adults or children. Interventions: SsK12 as active treatment or prophylaxis, against pharyngotonsillitis. Methods: Literature search. Results: Four articles were identified (1846 participants). All were deemed to be of poor quality using the Cochrane risk-of-bias assessment. Two trials studied SsK12 prophylaxis for streptococcal pharyngitis (children without history of recurrence). One compared daily administration of SsK12 to no treatment over 6 months (n ¼ 222, age 33e45 months), reporting significantly lower incidence in the SsK12 group (16.2% vs. 48.6%, p < 0.01), whereas another placebo-controlled RCT over four school terms (n ¼ 1314, 5 e14 years) found no significant difference (7.8% vs. 8.8%, p 0.34) with SsK12 (administered on school days). Another trial found daily SsK12 to significantly protect children (n ¼ 250, 6e7 years) against chronic adenoiditis exacerbation over 3 months compared to no treatment (71.7% vs. 100%, p < 0.0001). The one placebo-controlled RCT in adults that studied the use of SsK12 for acute pharyngotonsillitis (concurrently with penicillin) showed no significant benefit. In all trials, SsK12 was safe and well tolerated.Conclusions: SsK12 appears safe and well tolerated. However, further RCTs are required to establish its role as a prophylactic therapy, particularly among patients experiencing frequent exacerbations of pharyngitis. In the acute setting, SsK12 is unlikely to be effective if given concurrently with antibiotics; however, further RCTs should establish its role as an alternative to antibiotics in nonsevere cases or when prescribed after antibiotic therapy for the prevention of disease recurrence and/or secondary infection.

show abstract